1. Use of the conditional marketing authorization pathway for oncology medicines in Europe;Hoekman;Clin. Pharmacol. Ther.,2015
2. Garrido , M.V. Kristensen , F.B. Palmhøj Nielsen , C. Busse , R. Health technology assessment and health policy-making in Europe 2008
3. Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?;Bergmann;Ann. Oncol.,2014
4. Improving the contribution of regulatory assessment reports to health technology assessments-a collaboration between the European Medicines Agency and the European Network for Health Technology Assessment;Berntgen;Value Health,2014
5. European Medicines Agency, Science, Medicines, Health Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/07/WC500190555.pdf 2015